Viewing Study NCT01186861


Ignite Creation Date: 2025-12-24 @ 12:38 PM
Ignite Modification Date: 2026-01-13 @ 8:00 PM
Study NCT ID: NCT01186861
Status: COMPLETED
Last Update Posted: 2025-11-18
First Post: 2010-08-19
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Sponsor: Astellas Pharma Inc
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module